Acute lung injury, is a severe medical condition. Acute lung injury (ALI) risk factors include a variety of medications. However, a dearth of information on the frequency and course of drug-associated ALI, and the evidence is mainly restricted to case reports. Therefore, ALI is challenging to diagnose and is often determined by ruling out other potential causes. Drug interactions or the usage of certain drugs may induce toxicity. When no alternative metabolic pathway is available, lack of or extremely low enzyme activity may result in drug toxicity. To avoid hazardous side effects in the case of decreased enzyme activity, it is advised to lower the dosage or prescribe an alternate medication that is digested by a different, unaffected enzyme system. Increased enzyme activity, however, may result in the excessive manufacturing of harmful and sometimes reactive by-products. Therefore, a viable strategy to avoid lung harm is to be aware of a patient's drug metabolizing profile prior to prescribing medication. The aim of the current research is to better understand the part of Clinical Pharmacists in preventing acute lung injury induced by drugs. The study is prospective hospital-based, which comprised patients who satisfied the criteria for discharge while being cured in the Department of respiratory medicine, a tertiary care Hospital in Delhi, between March 2021 and January 2022. Standardized treatments were given to all individuals. Directly taken from the participants' computerized medical records, pertinent data was collected. SPSS 22.0 was used to analyse all the data.
Acute lung injury (ALI), drug, clinical pharmacist